Clinical Cancer Research Versailles No Abst Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mrena, J.
Right arrow Articles by Haglund, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mrena, J.
Right arrow Articles by Haglund, C.
Clinical Cancer Research Vol. 11, 7362-7368, October 15, 2005
© 2005 American Association for Cancer Research


Imaging, Diagnosis, Prognosis

Cyclooxygenase-2 Is an Independent Prognostic Factor in Gastric Cancer and Its Expression Is Regulated by the Messenger RNA Stability Factor HuR

Johanna Mrena1, Jan-Patrik Wiksten1, Alexandra Thiel2,3, Arto Kokkola1, Leena Pohjola2,3, Johan Lundin4, Stig Nordling2, Ari Ristimäki2,3 and Caj Haglund1,2

Authors' Affiliations: Departments of 1 Surgery and 2 Pathology, Helsinki University Central Hospital; 3 Molecular and Cancer Biology Research Program, Biomedicum Helsinki; and 4 Folkhälsan Research Centre, University of Helsinki, Helsinki, Finland

Requests for reprints: Caj Haglund, Department of Surgery, Helsinki University Central Hospital, P.O. Box 340, 00029 HUS Helsinki, Finland. Phone: 358-9-471-72427; Fax: 358-9-471-71403; E-mail: caj.haglund{at}hus.fi.

Purpose: Cyclooxygenase-2 (COX-2) promotes carcinogenesis and its expression associates with clinicopathologic characteristics in gastric cancer. HuR is an mRNA binding protein that controls the stability of certain transcripts including COX-2. We evaluated the prognostic significance of COX-2 and HuR expressions in gastric cancer and whether there exists a link between HuR and COX-2 expressions.

Experimental Design: The study included 342 consecutive patients with histologically confirmed gastric adenocarcinoma, of whom 321 patients had tissue specimens available for COX-2 and 316 for HuR immunohistochemistry. Specimens were stained by COX-2– and HuR-specific monoclonal antibodies and scored by two independent observers. Correlation to clinical data and survival was assessed. TMK-1 gastric adenocarcinoma cells were treated with small interfering RNA against HuR and expressions of HuR and COX-2 were detected by immunofluorescence and Western blot analysis.

Results: Patients with low COX-2 expression had a cumulative 5-year survival of 53% and those with high COX-2 expression had 16% (P < 0.0001). In multivariate analysis, COX-2 was an independent prognostic factor (P = 0.003). Cytoplasmic HuR expression was associated with high COX-2 expression (P < 0.0001) and with reduced survival (P = 0.004) whereas nuclear positivity for HuR was not. When TMK-1 cells were treated with HuR small interfering RNA, expressions of HuR and COX-2 were reduced.

Conclusions: High COX-2 is an independent prognostic factor in gastric cancer. Cytoplasmic expression of HuR associates with high COX-2 expression and with reduced survival, and tissue culture experiments show that HuR can regulate expression of COX-2 in gastric cancer cells.




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
D. A. Ayupova, M. Singh, E. C. Leonard, D. P. Basile, and B. S. Lee
Expression of the RNA-stabilizing protein HuR in ischemia-reperfusion injury of rat kidney
Am J Physiol Renal Physiol, July 1, 2009; 297(1): F95 - F105.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
W. Al-Ahmadi, M. Al-Ghamdi, L. Al-Haj, M. Al-Saif, and K. S. A. Khabar
Alternative polyadenylation variants of the RNA binding protein, HuR: abundance, role of AU-rich elements and auto-Regulation
Nucleic Acids Res., June 1, 2009; 37(11): 3612 - 3624.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. S. Park, I. G. Do, C. K. Park, W. K. Kang, J. H. Noh, T. S. Sohn, S. Kim, M.-J. Kim, and K.-M. Kim
Cyclooxygenase-2 Is an Independent Prognostic Factor in Gastric Carcinoma Patients Receiving Adjuvant Chemotherapy and Is Not Associated with EBV Infection
Clin. Cancer Res., January 1, 2009; 15(1): 291 - 298.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. D. Ortega, S. Sala, E. Espinosa, M. Gonzalez-Baron, and J. M. Cuezva
HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence
Carcinogenesis, November 1, 2008; 29(11): 2053 - 2061.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Doller, E.-S. Akool, A. Huwiler, R. Muller, H. H. Radeke, J. Pfeilschifter, and W. Eberhardt
Posttranslational Modification of the AU-Rich Element Binding Protein HuR by Protein Kinase C{delta} Elicits Angiotensin II-Induced Stabilization and Nuclear Export of Cyclooxygenase 2 mRNA
Mol. Cell. Biol., April 15, 2008; 28(8): 2608 - 2625.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Heinonen, R. Fagerholm, K. Aaltonen, O. Kilpivaara, K. Aittomaki, C. Blomqvist, P. Heikkila, C. Haglund, H. Nevanlinna, and A. Ristimaki
Prognostic Role of HuR in Hereditary Breast Cancer
Clin. Cancer Res., December 1, 2007; 13(23): 6959 - 6963.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. F.G. de Maat, C. J.H. van de Velde, N. Umetani, P. de Heer, H. Putter, A. Q. van Hoesel, G. A. Meijer, N. C. van Grieken, P. J.K. Kuppen, A. J. Bilchik, et al.
Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer
J. Clin. Oncol., November 1, 2007; 25(31): 4887 - 4894.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
J. F. Di Mari, J. I. Saada, R. C. Mifflin, J. D. Valentich, and D. W. Powell
HETEs enhance IL-1-mediated COX-2 expression via augmentation of message stability in human colonic myofibroblasts
Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G719 - G728.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X.-L. Li, J. B. Andersen, H. J. Ezelle, G. M. Wilson, and B. A. Hassel
Post-transcriptional Regulation of RNase-L Expression Is Mediated by the 3'-Untranslated Region of Its mRNA
J. Biol. Chem., March 16, 2007; 282(11): 7950 - 7960.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
J Mrena, J-P Wiksten, S Nordling, A Kokkola, A Ristimaki, and C Haglund
MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer.
J. Clin. Pathol., June 1, 2006; 59(6): 618 - 623.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Thiel, M. Heinonen, J. Rintahaka, T. Hallikainen, A. Hemmes, D. A. Dixon, C. Haglund, and A. Ristimaki
Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells
J. Biol. Chem., February 24, 2006; 281(8): 4564 - 4569.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.